The USPTO will host its first Clean Technology Partnership Meeting on Wednesday, April 27, 2011 in an effort to bring clean technology leaders together to share insights and ideas and provide perspective on how the USPTO can expand its clean technology programs. Foley’s J. Steven Rutt, Chair of the Nanotechnology Team and member of the Green Energy Technologies Team, will moderate the forum and lead a discussion on cleantech innovation, sharing insights from the firm’s soon-to-be released 2011 Annual Cleantech Patent Landscape Report.
Additional speakers include:
- Bruce Kisliuk, Assistant Deputy Commissioner for Patents, Mechanical Disciplines, USPTO
- Jacqueline Stone, Group Director TC 1600, USPTO
- Neil Feltham, Senior Patent Counsel, DuPont
- William S. Elias, General Counsel, UChicago Argonne, LLC
- Mike Nelson, Chief Technology Officer, NanoInk, Inc.
- Alan Brown, Executive Director, Pennsylvania NanoMaterials Commercialization Center
The meeting will be held at USPTO Headquarters in Alexandria, Virginia, from 1:00-5:00 p.m.
Related Insights
June 6, 2025
Energy Current
House Bill 3809 Adds Obligations to Battery Energy Storage Lessees in Texas
On May 29, 2025, House Bill No. 3809 was signed into law by Texas Governor Greg Abbott. Born out of a crop of bills regulating renewable…
June 23, 2025
Events
Third Annual Transaction Solutions Symposium
Foley & Lardner is sponsoring the Third Annual Transaction Solutions Symposium — a premier conference focused on de-risking strategies that enhance deal execution and business outcomes. Rishi Sodhi will be speaking as part of the Tax Liability Insurance: Current Trends, Controversies and Claims panel.
June 5, 2025
Health Care Law Today
GLP-1 Compounded Medications Targeted by Connecticut Attorney General
On May 21, 2025, the Connecticut Office of the Attorney General released a statement and sent letters to Connecticut weight loss clinics, med spas, medical practices and other businesses regarding allegedly or potentially unfair and deceptive conduct relating to compounded GLP-1 medications.